Alluvi, formerly BI 4744, presents a significant advance in obesity therapy. This dual activator targeting both glucagon-like peptide-1 and GIP sites demonstrates remarkable efficacy in clinical studies, possibly https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/